• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Abcam plc

    12/15/23 4:18:56 PM ET
    $ABCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABCM alert in real time by email
    S-8 POS 1 d562441ds8pos.htm S-8 POS S-8 POS

    As filed with the United States Securities and Exchange Commission on December 15, 2023

    Registration No. 333-252514

    Registration No. 333-257893

    Registration No. 333-263946

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    Post-Effective Amendment No. 1 (333-252514)

    Post-Effective Amendment No. 1 (333-257893)

    Post-Effective Amendment No. 1 (333-263946)

    to

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Abcam Limited

    (Exact name of registrant as specified in its charter)

     

     

     

    United Kingdom   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    Discovery Drive

    Cambridge Biomedical Campus

    Cambridge, CB2 0AX

    United Kingdom

      Not Applicable
    (Address of Principal Executive Offices)   (Zip Code)

    ABCAM PLC LONG-TERM INCENTIVE PLAN

    ABSHARE

    THE ABCAM PLC ANNUAL BONUS PLAN

    ABCAM 2005 SHARE OPTION SCHEME

    THE ABCAM 2015 SHARE OPTION PLAN

    ABCAM PLC PROFITABLE GROWTH INCENTIVE PLAN

    ABCAM PLC GROWTH PLAN

    (Full title of the plan)

    Abcam Inc.

    152 Grove Street

    Suite 1100

    Waltham, Massachusetts

    02453

    (Name and address of agent for service)

    (888) 772-2226

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Lorenzo Corte, Esq.

    Skadden, Arps, Slate, Meagher & Flom (UK) LLP

    22 Bishopsgate

    London EC2M 4BQ

    United Kingdom

    +44 20 7519 7000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated Filer   ☒    Accelerated Filer   ☐
    Non-Accelerated Filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (the “Registration Statements”) of Abcam Limited, a private limited company under the laws of England and Wales (“Abcam”):

     

      •  

    Registration Statement on Form S-8, File No. 333-252514, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 28, 2021, pertaining to 4,607,314 ordinary shares, nominal value £0.002 per share, of Abcam (“Ordinary Shares”), issuable under (i) the Abcam plc Long-Term Incentive Plan, (ii) Abshare, (iii) the Abcam plc Annual Bonus Plan, (iv) the Abcam 2005 Share Option Scheme and (v) the Abcam 2015 Share Option Plan;

     

      •  

    Registration Statement on Form S-8, File No. 333-257893, filed with the SEC on July 14, 2021, pertaining to 7,936,170 Ordinary Shares issuable under the Abcam plc Profitable Growth Incentive Plan; and

     

      •  

    Registration Statement on Form S-8, File No. 333-263946, filed with the SEC on March 29, 2022, pertaining to 3,500,000 Ordinary Shares issuable under the Abcam plc Growth Plan.

    On December 6, 2023, Diadem Holdco Limited (“Purchaser”), an indirect wholly owned subsidiary of Danaher Corporation (“Danaher”), acquired all of the issued and outstanding Ordinary Shares and American depositary shares of the Company (other than certain ordinary shares held by Danaher) pursuant to an agreement dated August 26, 2023, by and among the Company, Danaher and Purchaser, in accordance with a scheme of arrangement (the “Scheme”) under Part 26 of the U.K. Companies Act 2006.

    As a result of the Scheme, the Company has terminated any and all offerings of the Ordinary Shares pursuant to the Registration Statements. In accordance with an undertaking contained in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the Ordinary Shares registered under the Registration Statements that remain unsold at the termination of the offering, the Company hereby removes from registration all of the Ordinary Shares registered but unsold under the Registration Statements as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, United Kingdom, on December 15, 2023.

     

    ABCAM LIMITED

    By:

     

    /s/ Alan Hirzel

    Name:

     

    Alan Hirzel

    Title:

     

    Chief Executive Officer

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.


    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF REGISTRANT

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Abcam Limited has signed this registration statement on December 15, 2023.

     

    ABCAM INC.

    By:

     

    /s/ Theresa Boni

    Name:

     

    Theresa Boni

    Title:

     

    Assistant Secretary

    Get the next $ABCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABCM

    DatePrice TargetRatingAnalyst
    6/20/2023$23.00 → $22.00Outperform → Sector Perform
    RBC Capital Mkts
    6/16/2023$25.00Neutral → Buy
    BofA Securities
    12/14/2022$15.00Hold
    Deutsche Bank
    More analyst ratings

    $ABCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danaher Completes Acquisition of Abcam

      WASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023. As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended. The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS

      12/6/23 7:30:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘). Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme. Closing of the T

      12/4/23 4:01:00 PM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), today announced that all Identified Clearances required in connection with the Transaction have been obtained from the relevant Governmental Authorities. The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England and Wales and the satisfaction or waiver (if applicable) of certain other customary closing conditions as set out in Par

      11/17/23 7:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials

    $ABCM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Abcam plc

      15-12G - Abcam plc (0001492074) (Filer)

      12/18/23 4:17:02 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:24:56 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:21:28 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abcam downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Abcam from Outperform to Sector Perform and set a new price target of $22.00 from $23.00 previously

      6/20/23 7:17:42 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Abcam upgraded by BofA Securities with a new price target

      BofA Securities upgraded Abcam from Neutral to Buy and set a new price target of $25.00

      6/16/23 7:25:35 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Abcam with a new price target

      Deutsche Bank initiated coverage of Abcam with a rating of Hold and set a new price target of $15.00

      12/14/22 7:33:18 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Leadership Updates

    Live Leadership Updates

    See more
    • Jonathan Milner issues Open Letter to shareholders of Abcam plc

      Jonathan Milner issues Open Letter to shareholders of Abcam plc Highlights Company's loss of focus on governance, execution and cost control leading to value destruction and a share price materially below where it should be Outlines Milner's plan to restore shareholder trust and value and make Abcam the world leading antibody company once again CAMBRIDGE, England, 12 June 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, has today issued an open letter to the Company's shareholders calling for the removal of Peter Allen, Michael S. Baldock and Sally W. Crawford as Directors of th

      6/12/23 7:00:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders

      Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders Delivers Open Letter to Abcam shareholders Follows sustained period of operational underperformance since the start of 2020 and a track record of value destruction under the current Board and leadership team Critical for shareholders to have a platform to exert their right to restore focus for Abcam on governance, execution, and cost control to elevate it to the valuation it rightly deserves CAMBRIDGE, England, 17 May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.3% of the Company, a

      5/17/23 9:15:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Abcam: Appointment of Vice President of Investor Relations

      CAMBRIDGE, England, June 27, 2022 /PRNewswire/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (NASDAQ:ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations.     Tommy, who will be based in our Waltham, MA office, has over 20 years' experience in the life sciences sector, largely focused in the area of research tools. He joins Abcam from Avantor, where he was Vice President, Investor Relations for several years. Prior to this he was Vice President of Investor Relations, and then Chief Financial Officer of Global Services at Perkin Elmer. Before joining Perkin Elmer, Tommy spent eight

      6/27/22 2:00:00 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Financials

    Live finance-specific insights

    See more
    • Jonathan Milner issues Open Letter to shareholders of Abcam plc

      Jonathan Milner issues Open Letter to shareholders of Abcam plc Urges shareholders to Vote AGAINST the proposed acquisition of Abcam by Danaher Corporation CAMBRIDGE, England, 28 September 2023 – Dr. Jonathan Milner, the founder and one of the largestinvestors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.15%, todayissued an open letter to the Company's shareholders announcing his "Vote AGAINST" campaign and providing them with the opportunity to send a clear message to the Board that they are dissatisfied with the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher") and Abcam's governance, execution and cost control.

      9/28/23 2:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board

      Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board CAMBRIDGE, England, 14 September 2023 – Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.14%, today announces his decision to vote against the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher"). In addition to this, he will formally request the Abcam Board of Directors to convene a General Meeting ("EGM") with the purpose of replacing the Company's Board, including the current CEO, CFO and Chairman. Jonathan Milner's decision to oppose the acquisition is informed by e

      9/14/23 8:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Danaher to acquire Abcam for $24.00 per Share

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) (‘Danaher') will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction'). The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pat

      8/28/23 7:35:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials

    $ABCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      2/12/24 5:24:03 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      1/12/24 11:40:16 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Abcam plc (Amendment)

      SC 13D/A - Abcam plc (0001492074) (Subject)

      12/8/23 4:30:10 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care